New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2012
16:16 EDTAZN, STP, NSRGY, TRGT, YGE, MYGN, TSL, RIO, BHP, TIFOn The Fly: Closing Wrap
Stocks on Wall Street were lower on concerns of slowing growth in China. The futures barely reacted to February U.S. housing data, which showed starts were lower than expected but building permits were higher. The futures action led to a lower open for the broader market. The averages found a level in the first 30 minutes of trading where they sat and eventually began to drift higher. The market moved generally higher until the last hour of the session but the averages were never able to retake the baseline to continue their six day winning streak... ECONOMIC EVENTS: In the U.S., homebuilders began construction on a seasonally adjusted annual rate of 698,000 homes in February, down 1.1% from a month ago. Building permits jumped 5.1%, versus expectations for an increase of 0.6%. In China, a report said that home prices dropped in 45 Chinese cities last month and the country increased its gas and diesel prices for the second time in less than six weeks... MARKET NEWS: BHP Billiton (BHP) was widely quoted as stating that Chinese iron ore demand growth was "flattening," but the company came out and said that the slowdown had been discussed before and was not new information. Also, both BHP and rival Rio Tinto (RIO) confirmed plans to expand production in China even further. Still, BHP's confirmation along with other signals of a slowdown in China was attributed as a significant catalyst for today's market pull-back... Saudi Arabia said it is ready to meet any shortfalls in global oil supplies which, along with China's news, caused oil prices to fall 2%, weighing on the Energy sector of the S&P... (AMZN) moved up 3.67% following its $775M purchase of Kiva Systems, a maker of robots and other material handling technology... MAJOR MOVERS: Among the notable gainers was Tiffany (TIF), up $4.59, or 6.68%, to $73.27, after its earnings missed expectations but its FY12 guidance beat the Street's view. Also higher were a number of Chinese solar companies, including Yingli Green Energy (YGE), up 46c, or 12.07%, to $4.27, Suntech (STP), up 44c, or 14.06%, to $3.57, and Trina Solar (TSL), up 61c, or 7.85%, to $8.38, following the U.S. Commerce Department's decision to impose tariffs of less than 5% on the companies, which was well below the 20% to 30% that was forecast by some analysts. Noteworthy losers included Targacept (TRGT), down $2.22, or 29.96%, to $5.19, after it abandoned plans to seek approval for a depression drug it was developing in partnership with AstraZeneca (AZN), and Myriad Genetics (MYGN), down $1.33, or 5.19%, to $24.31, after the Supreme Court ruled that two patents held by Nestle (NSRGY) for certain personalized medicine products are invalid because the patents utilize "laws of nature" without adding significant additional features to those laws... INDICES: The Dow fell 68.94, or 0.52%, to 13,170.19; the Nasdaq lost 4.17, or 0.14%, to 3,074.15; and the S&P 500 dropped 4.23, or 0.30%, to 1,405.52.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
November 23, 2015
05:36 EDTMYGNGenomic Health upgraded to Buy from Neutral at UBS
Subscribe for More Information
November 20, 2015
07:31 EDTAZNLabcyte, AstraZeneca partner to develop acoustic liquid handling system
Labcyte announced a partnership with AstraZeneca to develop a state-of-the-art automated pharmaceutical compound management system based on its revolutionary Echo acoustic liquid handling technology. The new system, which will employ storage tubes compatible with acoustic liquid handling, will be deployed at the AstraZeneca MRC UK Centre for Lead Discovery in Cambridge.
06:58 EDTTSLTrina Solar volatility elevated into Q3 and outlook
Trina Solar December call option implied volatility is at 69, January is at 62; compared to its 52-week range of 38 to 91, suggesting large near term price movement into the expected release of Q2 results on November 23.
06:09 EDTAZNSanofi, AstraZeneca to exchange more than 210,000 compounds
Subscribe for More Information
November 19, 2015
07:19 EDTMYGNCMS decision a big positive for Myriad Genetics, says Stephens
Subscribe for More Information
06:40 EDTBHPBHP Billiton backs dividend policy amid profit slump, CNBC reports
BHP Billiton (BHP) defended its dividend policy amid a drop in share prices and profits slump this year as well as weak China growth and a recent mine disaster in Brazil, CNBC reports. BHP chairman Jacques Nasser said at the company's annual meeting that the dividend policy is the result of "appropriate capital management," the report says. In addition, the company said it and joint venture partner Vale (VALE) will be commissioning an external probe of the Samarco dam spill, the report says. Reference Link
November 18, 2015
16:43 EDTAZNBIND Therapeutics gets $4M milestone payment from AstraZeneca
Subscribe for More Information
10:02 EDTTIFHigh option volume stocks: CIT TDC MAR JNK EIX TIF NBG DSX FCS ARG
Subscribe for More Information
09:49 EDTMYGNCMS reversal removes 'huge overhang' for CareDx, says Mizuho
Subscribe for More Information
08:11 EDTAZNIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:02 EDTAZNBIND says AstraZeneca initiates patient dosing in AZD2811 Phase 1 trial
Subscribe for More Information
07:59 EDTTIFTiffany price target lowered to $90 from $97 at Cowen
Cowen lowered its price target on Tiffany to $90 from $97 citing near term caution on global macro conditions. The firm remains positive longer term citing product innovation, geographic expansion of it store base and improving CRM capabilities. Cowen reiterated its Outperform rating on Tiffany shares.
07:26 EDTAZNZS Pharma downgraded to Neutral from Buy at Citi
Subscribe for More Information
November 17, 2015
10:20 EDTTIFOptions with increasing implied volatility
Options with increasing implied volatility: SGMS HZNP CSC ULTA RH BURL GME AEO BBRY TIF
10:00 EDTBHPOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Airgas (ARG) downgraded on valuation at KeyBanc... BHP Billiton (BHP) downgraded to Neutral from Buy at Clarksons Platou... Chesapeake (CHK) downgraded to Neutral from Buy at Sterne Agee CRT... ChipMOS (IMOS) downgraded to Equal Weight from Overweight at Morgan Stanley... Clovis (CLVS) downgraded to Neutral from Conviction Buy at Goldman... Cooper Companies (COO) downgraded to Market Perform from Outperform at Wells Fargo... Five Below (FIVE) downgraded to Neutral from Buy at Sterne Agee CRT... Grainger (GWW) downgraded to Underweight from Neutral at Atlantic Equities... Hess Corp. (HES) downgraded to Perform from Outperform at Oppenheimer... J Sainsbury (JSAIY) downgraded to Neutral from Buy at Citi... Kindred Biosciences (KIN) downgraded to Market Perform from Outperform at BMO Capital... Leju (LEJU) downgraded to Neutral from Buy at BofA/Merrill... Lombard Medical (EVAR) downgraded to Equal Weight from Overweight at Barclays... Osiris (OSIR) downgraded to Sell from Hold at Brean Capital... Polaris Industries (PII) downgraded on anemic ORV growth at Wedbush... SQM (SQM) downgraded to Hold from Buy at HSBC... Southwestern Energy (SWN) downgraded to Underperform from Neutral at Sterne Agee CRT... Starwood (HOT) downgraded to Outperform from Buy at CLSA... Urban Outfitters (URBN) downgraded to Hold from Buy at Cantor... WM Morrison (MRWSY) downgraded to Sell from Neutral at Citi... adidas (ADDDY) downgraded to Sector Perform from Outperform at RBC Capital... athenahealth (ATHN) downgraded to Underweight from Equal Weight at Barclays.
09:15 EDTBHPBHP Billiton downgraded to Neutral from Buy at Clarksons Platou
Subscribe for More Information
07:03 EDTAZNCerulean, AstraZeneca partner to evaluate LYNPARZA, CRLX101 combo
Cerulean (CERU) announced that it has entered into a collaboration with AstraZeneca (AZN) and the National Cancer Institute, part of the National Institutes of Health, to study LYNPARZA and CRLX101. The collaboration will explore the synergistic effects of AstraZeneca's LYNPARZA, a poly ADP ribose polymerase inhibitor, and CRLX101, Cerulean's inhibitor of topoisomerase 1. The NCI will conduct a combination Phase I/IIa trial in the Branch led by Yves Pommier, M.D., Ph.D., Chief of the Developmental Therapeutics Branch.
06:17 EDTBHPBHP Billiton reviewing all dams worldwide, U.K. Times reports
BHP Billiton (BHP) CEO Andrew Mackenzie told analysts and investors at the company's annual general meeting that the company is reviewing all of its dams worldwide after the Samarco mudslide in Brazil killed at least nine people, The U.K. Times reports. Mackenzie also said BHP is considering moving away from the arrangement under which mines that it partly owns are managed by committee rather than by a single operator; the Samarco mine is half run by BHP, with the remainder owned by Vale (VALE). Reference Link
06:02 EDTAZNAstraZeneca drug to cost over $12K for a month's supply, Reuters reports
Subscribe for More Information
05:37 EDTAZNClovis downgraded to Neutral from Conviction Buy at Goldman
Goldman Sachs analyst Terence Flynn downgraded Clovis Oncology (CLVS) to Neutral from Conviction Buy citing limited visibility on the path to FDA approval following yesterday's update on the company's lung cancer drug Roci. The drug now has a less compelling profile relative to AstraZeneca's (AZN) Tagrisso, Flynn tells investors in a research note. He cut his price target for shares to $23 from $123. Clovis closed yesterday down $66.19, or 70%, to $30.24.
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use